PBH

AI Memo

Prestige Consumer Healthcare

As of 2026-09-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q1 FY2027 beat and raised outlook • 2026-08-06

Base target: $55 / p=55% prob

Biggest risk

Approximately $2 billion of net debt, acquisition-integration demands, Clear Eyes variability, supply-chain uncertainty, and the operations leadership transition could limit earnings durability or compress valuation.

Invalidation

Break below $47 or thesis failure.

What would change my mind?

Diversified branded consumer-health products, Q1 execution above expectations, raised fiscal 2027 guidance, acquisition contributions, and record adjusted free cash flow support a cautiously positive outlook.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-02

Base target

$55

p=55%

Bull target

$67

p=25%

Bear target

$47

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Operations leadership transition
Acquisition integration and deleveraging
Diversified branded consumer-health products, Q1 execution above expectations, raised fiscal 2027 guidance, acquisition contributions, and record adjusted free cash flow support a cautiously positive outlook.

BearKey bullets

Approximately $2 billion of net debt increases sensitivity to integration execution, cash-flow conversion, and deleveraging progress.
[#SEC-8K-2026-08-06]
Clear Eyes performance and supply availability were below expectations or variable.

WatchKey bullets

Q1 FY2027 beat and raised outlook

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $55 (p=55%)

Target spread vs base: +22% / -14%

Scenario probabilities

Bull Target: $67 (p=25%)Base Target: $55 (p=55%)Bear Target: $47 (p=20%)

Commentary

Recent news is constructive because of the Q1 beat, raised outlook, acquisitions, and record adjusted free cash flow, but the immediate market reaction appears limited. Social, options, short-interest, employee-sentiment, and post-print analyst-revision data are unavailable; the thesis remains a cautious monitoring view rather than a high-conviction rerating call.

As of 2026-09-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Operations leadership transition
Acquisition integration and deleveraging

Scenarios

Bull Target (Scenario probability)

$67 / p=25% prob

Base Target (Scenario probability)

$55 / p=55% prob

Bear Target (Scenario probability)

$47 / p=20% prob

Analysis 2026-09-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.65

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
Q1 FY2027 beat and raised outlook
Q1 revenue rose 6.5% to $265.7 million, organic sales grew 3.2%, adjusted EPS was $0.98, and adjusted free cash flow reached a quarterly record of $83.7 million. Management raised fiscal 2027 revenue guidance to $1.290-$1.315 billion and adjusted EPS guidance to $4.55-$4.65. [#SEC-8K-2026-08-06]
Prob 90.00% • Move 3.00% • Priced-in 80.00%

Short-term Catalysts

Next few weeks

Operations leadership transition
2026-08-14
The Senior Vice President of Operations retired effective August 14, 2026. No material disruption is identified in the filing, but the transition warrants near-term execution monitoring. [#8-K-2026-08-14]
Prob 100% • Move -2% • Priced-in 90%

Long-term Catalysts

Months to a year

Acquisition integration and deleveraging
2027-03-31
The Breathe Right and LaCorium acquisitions expand the portfolio, while approximately $2 billion of net debt makes integration execution, free-cash-flow conversion, and deleveraging important medium-term drivers. [#SEC-8K-2026-08-06]
Prob 70% • Move 8% • Priced-in 45%

Risks

Approximately $2 billion of net debt increases sensitivity to integration execution, cash-flow conversion, and deleveraging progress. [#SEC-8K-2026-08-06]
Clear Eyes performance and supply availability were below expectations or variable. [#SEC-8K-2026-08-06]
Management cited heightened uncertainty from supply-chain constraints, inflation, and geopolitical events. [#PR-EARNINGS-2026-08-13]
Post-earnings analyst revisions, options data, short interest, employee sentiment, and social coverage are unavailable or insufficient.
The Senior Vice President of Operations retired effective August 14, 2026, creating a modest execution-monitoring risk. [#8-K-2026-08-14]

Peers

Symbol	Summary
AMLX	Similar market capitalization and broad sector classification, but development-stage pharmaceutical exposure makes it a loose operating comparable to PBH.
CDNA	Similar market capitalization and sector classification, but diagnostics exposure limits comparability with PBH's diversified consumer-health portfolio.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-02

Loading AI feed…

Symbol

Summary

AMLX

Similar market capitalization and broad sector classification, but development-stage pharmaceutical exposure makes it a loose operating comparable to PBH.

CDNA

Similar market capitalization and sector classification, but diagnostics exposure limits comparability with PBH's diversified consumer-health portfolio.